Consistent with the findings of Lankoff et al., in the phase II clinical trial of Hofman and colleagues, grade 3-4 thrombocytopenia was observed in 27% of castration-resistant prostate cancer (CRPC) patients administered with another PSMA-targeting radioprobe (Lutetium-177 (177Lu)-PSMA) [189]. The gene discussed is FOLH1; the disease is Thrombocytopenia.